Correction: Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats (PLoS ONE (2014) 9, 3 (e91512) DOI: 10.1371/journal.pone.0091512);Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Feng, Qiqi ^a,b   Ma, Yuxin ^a,c   Mu, Shuhua ^a   Wu, Jiajia ^a   Chen, Si ^a   OuYang, Lisi ^a   Lei, Wanlong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; CHOLINE ACETYLTRANSFERASE; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROPEPTIDE Y; PARVALBUMIN; PHOSPHOPROTEIN DARPP 32; QUINOLINIC ACID; NERVE PROTEIN;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; HISTOCHEMISTRY; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INTERNEURON; MALE; MOTOR DYSFUNCTION; NERVE FUNCTION; NERVE PROJECTION; NEUROANATOMY; NEUROPATHOLOGY; NONHUMAN; PROTEIN ANALYSIS; RAT; WESTERN BLOTTING; ANIMAL; CELL COUNT; CYTOLOGY; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; CELL COUNT; CORPUS STRIATUM; IMMUNOHISTOCHEMISTRY; INTERNEURONS; MALE; NERVE TISSUE PROTEINS; NEURONS; QUINOLINIC ACID; RATS;

EID: 84898438929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096966     Document Type: Erratum

References (59)

1. Walker FO (2007) Huntington's disease. Lancet 369: 218-228.
2. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, et al. (1987) Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 46: 12-27. (Pubitemid 17232251)
3. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
4. Albin RL, Tagle DA (1995) Genetics and molecular biology of Huntington's disease. Trends Neurosci 18: 11-14.
5. Claes S, Van Zand K, Legius E, Dom R, Malfroid M, et al. (1995) Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 52: 749-753.
6. Kim SH, Thomas CA, Andre VM, Cummings DM, Cepeda C, et al. (2011) Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro 3: e60.
7. Cowan CM, Raymond LA (2006) Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 75: 25-71. (Pubitemid 44375081)
8. Bithell A, Johnson R, Buckley NJ (2009) Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease. Biochem Soc Trans 37: 1270-1275.
9. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90: 230-245.
10. Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95: 1521-1540. (Pubitemid 41804051)
11. Han I, You Y, Kordower JH, Brady ST, Morfini GA (2010) Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem 113: 1073-1091.
12. Bruyn RP, Stoof JC (1990) The quinolinic acid hypothesis in Huntington's chorea. J Neurol Sci 95: 29-38. (Pubitemid 20034383)
13. Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81: 163-221.
14. Roberts RC, Ahn A, Swartz KJ, Beal MF, DiFiglia M (1993) Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp Neurol 124: 274-282. (Pubitemid 24041774)
15. Guillemin GJ (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J 279: 1356-1365.
16. Durieux PF, Schiffmann SN, de Kerchove DA (2011) Targeting neuronal populations of the striatum. Front Neuroanat 5: 40.
17. Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL (1998) Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 22: 1217-1240. (Pubitemid 28511596)
18. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, et al. (1997) Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 79: 45-56. (Pubitemid 27244999)
19. Ngai LY, Herbert J (2005) Glucocorticoid enhances the neurotoxic actions of quinolinic acid in the striatum in a cell-specific manner. J Neuroendocrinol 17: 424-434.
20. Figueredo-Cardenas G, Chen Q, Reiner A (1997) Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 146: 444-457. (Pubitemid 27381851)
21. Meade CA, Figueredo-Cardenas G, Fusco F, Nowak TJ, Pulsinelli WA, et al. (2000) Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease. Exp Neurol 166: 307-323.
22. Haik KL, Shear DA, Schroeder U, Sabel BA, Dunbar GL (2000) Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease. Exp Neurol 163: 430-439. (Pubitemid 30399093)
23. Boegman RJ, Parent A (1988) Differential sensitivity of neuropeptide Y, somatostatin and NADPH-diaphorase containing neurons in rat cortex and striatum to quinolinic acid. Brain Res 445: 358-362. (Pubitemid 18085454)
24. MacKenzie GM, Jenner P, Marsden CD (1995) The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum. Neuroscience 67: 357-371.
25. Mu S, OuYang L, Liu B, Zhu Y, Li K, et al. (2011) Preferential interneuron survival in the transition zone of 3-NP-induced striatal injury in rats. J Neurosci Res 89: 744-754.
26. Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates. United States: ACADEMIC PRESS. 1-456 p.
27. Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858.
28. Packard MG, Knowlton BJ (2002) Learning and memory functions of the Basal Ganglia. Annu Rev Neurosci 25: 563-593. (Pubitemid 34748029)
29. Voogd J, Feirabend HKP (1981) Methods in neurobiology, vol 2. New York: Elsevier. 301-364 p.
30. Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, et al. (1995) Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 65: 397-407.
31. Bates GP, Mangiarini L, Mahal A, Davies SW (1997) Transgenic models of Huntington's disease. Hum Mol Genet 6: 1633-1637. (Pubitemid 27401605)
32. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, et al. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171. (Pubitemid 16022019)
33. Perez-De LCV, Carrillo-Mora P, Santamaria A (2012) Quinolinic Acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 5: 1-8.
34. Guidetti P, Schwarcz R (2003) 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol 527: 137-145. (Pubitemid 38197638)
35. Wolfensberger M, Amsler U, Cuenod M, Foster AC, Whetsell WJ, et al. (1983) Identification of quinolinic acid in rat and human brain tissue. Neurosci Lett 41: 247-252. (Pubitemid 14237221)
36. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, et al. (2009) Effects of Kynurenine Pathway Metabolites on Intracellular NAD Synthesis and Cell Death in Human Primary Astrocytes and Neurons. Int J Tryptophan Res 2: 61-69.
37. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17: 455-461. (Pubitemid 39574879)
38. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ (2009) Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16: 77-86.
39. Kalonia H, Kumar P, Kumar A (2011) Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats. Behav Brain Res 216: 220-228.
40. Massouh M, Wallman MJ, Pourcher E, Parent A (2008) The fate of the large striatal interneurons expressing calretinin in Huntington's disease. Neurosci Res 62: 216-224.
41. Sawa A, Tomoda T, Bae BI (2003) Mechanisms of neuronal cell death in Huntington's disease. Cytogenet Genome Res 100: 287-295. (Pubitemid 37467816)
42. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, et al. (1995) In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 6: 1053-1057.
43. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, et al. (1995) DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 133: 265-272.
44. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE (1995) Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 15: 3775-3787.
45. Sanchez MR, Friedlander RM (2001) Caspases in Huntington's disease. Neuroscientist 7: 480-489.
46. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, et al. (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11: 424-438. (Pubitemid 38489420)
47. Tasset I, Perez-De LCV, Elinos-Calderon D, Carrillo-Mora P, Gonzalez-Herrera IG, et al. (2010) Protective effect of tert-butylhydroquinone on the quinolinic-acid-induced toxicity in rat striatal slices: role of the Nrf2-antioxidant response element pathway. Neurosignals 18: 24-31.
48. Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, et al. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol 47: 80-86. (Pubitemid 30033653)
49. Tarawneh R, Galvin JE (2010) Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med 26: 125-147.
50. Meade CA, Figueredo-Cardenas G, Fusco F, Nowak TJ, Pulsinelli WA, et al. (2000) Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease. Exp Neurol 166: 307-323.
51. Figueredo-Cardenas G, Harris CL, Anderson KD, Reiner A (1998) Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp Neurol 149: 356-372. (Pubitemid 28115074)
52. Cicchetti F, Prensa L, Wu Y, Parent A (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res Brain Res Rev 34: 80-101.
53. Cicchetti F, Gould PV, Parent A (1996) Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease. Brain Res 730: 232-237. (Pubitemid 26305345)
54. Kawaguchi Y (1993) Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J Neurosci 13: 4908-4923.
55. Tepper JM, Tecuapetla F, Koos T, Ibanez-Sandoval O (2010) Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat 4: 150.
56. Tepper JM, Bolam JP (2004) Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol 14: 685-692. (Pubitemid 39576198)
57. Smith R, Chung H, Rundquist S, Maat-Schieman ML, Colgan L, et al. (2006) Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet 15: 3119-3131. (Pubitemid 44605494)
58. Davies SW, Roberts PJ (1988) Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum. Neuroscience 26: 387-393.
59. Goldberg JA, Reynolds JN (2011) Spontaneous firing and evoked pauses in the tonically active cholinergic interneurons of the striatum. Neuroscience 198: 27-43.